Skip to search formSkip to main contentSkip to account menu

orteronel

Known as: Androgen Synthesis Inhibitor TAK-700, 6-((7S)-7-hydroxy-6,7-dihydro-5h-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthalenecarboxamide, 6-((7S)-7-hydroxy-6,7-dihydro-5H-pyrrolo(1,2-c)imidazol-7-yl)-N-methyl-2-naphthamide 
An orally bioavailable non-steroidal androgen synthesis inhibitor of steroid 17alpha-monooxygenase (17,20 lyase) with potential antiandrogen activity… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

ImidazolesNaphthalenes
NCIt Antineoplastic Agent Terminology

Narrower (1)

TAK-700

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2016
Review
2016
Incidence and relative risk of adverse events of special interest in patients with castration resistant prostate cancer treated with CYP-17 inhibitors: A meta-analysis of published trials.
Review
2015
Review
2015
CYP17A1 inhibitors in castration-resistant prostate cancer
Highly Cited
2015
Highly Cited
2015
Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that…
PURPOSE Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined… 
Review
2015
Review
2015
Battling resistance mechanisms in antihormonal prostate cancer treatment: Novel agents and combinations.
2014
2014
Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Purpose: Orteronel (TAK-700) is an investigational, nonsteroidal, oral, inhibitor of androgen synthesis with greater specificity… 
Review
2014
Review
2014
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
As the first in class steroid 17α-hydroxylase/C17,20-lyase (CYP17) inhibitor, abiraterone acetate (of which the active metabolite… 
Review
2012
Review
2012
Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists
Gonadotropin‐releasing hormone agonists and antagonists provide androgen‐deprivation therapy for prostate cancer. Unlike agonists… 
Review
2012
Review
2012
Targeting the androgen receptor in the management of castration-resistant prostate cancer: rationale, progress, and future directions.
Since the year 2000, tremendous progress has been made in the understanding of castration-resistant prostate cancer (crpc), a… 
Review
2011
Review
2011
Targeting Continued Androgen Receptor Signaling in Prostate Cancer
Prostate cancer is the most common cancer and the second leading cause of death from cancer in males in most Western countries… 
Highly Cited
2011
Highly Cited
2011
Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)